Jazz Pharmaceuticals, Inc. (JAZZ) Tops Q4 EPS by 11c; Issues FY13 Outlook

February 26, 2013 4:09 PM

Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q4 EPS of $1.53, $0.11 better than the analyst estimate ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found